BLUEJAY DIAGNOSTICS, INC. (BJDX) SEC News March 12, 2026, 16:24 UTC 0 1 comments (99% Neutral) BLUEJAY DIAGNOSTICS, INC. (BJDX) Provides Update on intended for critical care conditions Comment Full text
ENVVENO MEDICAL CORPORATION (NVNO) SEC News March 12, 2026, 16:13 UTC 0 1 comments 📋 Duhay Francis (Director) plans to sell 140 shares of enVVeno Medical Corp (at $11.52 each, total $2K) Filed: Mar 12, 2026 | ID: 000173 Comment Full text
ZIMMER BIOMET HOLDINGS, INC. (ZBH) SEC News March 12, 2026, 16:04 UTC 0 1 comments 📋 Winkler Lori (Officer) plans to sell 3K shares of ZIMMER BIOMET HOLDINGS, INC. (at $94.66 each, total $251K) Filed: Mar 12, 2026 | ID: 002241 Comment Full text
COYA THERAPEUTICS, INC. (COYA) SEC News March 12, 2026, 15:53 UTC 0 0 comments New Form SCHEDULE 13G - Coya Therapeutics, Inc. <b>Filed:</b> 2026-03-12 <b>AccNo:</b> 0001575872-26-000104 <b>Size:</b> 12 KB Comment Full text
MERCK & COMPANY, INC. (MRK) SEC News March 12, 2026, 14:53 UTC 0 0 comments New Form 3 - Merck & Co., Inc. <b>Filed:</b> 2026-03-12 <b>AccNo:</b> 0000310158-26-000070 <b>Size:</b> 6 KB Comment Full text
SYRA HEALTH CORP. (SYRA) SEC News March 12, 2026, 13:29 UTC 0 1 comments (30% Negative) SYRA HEALTH CORP. (SYRA) Reports Q1 2026 Financial Results Comment Full text
PULSE BIOSCIENCES, INC (PLSE) SEC News March 12, 2026, 13:20 UTC 0 1 comments (99% Neutral) PULSE BIOSCIENCES, INC (PLSE) Announces Enrollment Update for Center Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment Comment Full text
KEZAR LIFE SCIENCES, INC. (KZR) SEC News March 12, 2026, 13:11 UTC 0 1 comments (90% Positive) KEZAR LIFE SCIENCES, INC. (KZR) Announces Business Combination Comment Full text
ATRICURE, INC. (ATRC) SEC News March 12, 2026, 12:52 UTC 2 1 comments Director WHITE ROBERT S. 🟡 adjusted position in 0 shares (1 derivative) of AtriCure, Inc. (ATRC) at $14.99 Transaction Date: Mar 10, 2026 | Filing ID: 000002 Comment Full text
ULTRAGENYX PHARMACEUTICAL INC. (RARE) SEC News March 12, 2026, 12:45 UTC 0 1 comments (75% Positive) ULTRAGENYX PHARMACEUTICAL INC. (RARE) Announces Clinical Development Update Comment Full text